Danish drug maker Novo Nordisk, a leading producer of diabetes drugs, recently announced it extended its COVID-19 Patient Assistance Program until June 30, 2021 for individuals who have lost health insurance coverage due to a change in job status associated with the pandemic. The company actually announced at the beginning of 2020 new programs to support a growing number of patients facing economic challenges. Of course, the pandemic onset occurred just after leading to what is turning into an economic crisis. Hence, Novo Nordisk added to the programs such as Novocare.com to help patients who were not able to afford medications. Recently, the company issued a press release announcing updates to its “affordability programs.” Although Novo Nordisk, along with Sanofi and Lilly, have been named in 2019 in price gouging lawsuits associated with insulin, TrialSite reported they were responding to pressures with various price breaks. The company’s attempts to help those in need in what are very difficult times are appreciated. TrialSite has many viewers that have commented or sent messages about insulin, diabetic drugs and the pharma companies that make them. TrialSite shares this recent Novo Nordisk update.
Notable Novo Nordisk Affordability Program updates
- COVID-19 Patient Assistance Program: Launched in April 2020, people with diabetes using Novo Nordisk insulin who lost health insurance coverage because of a change in job status due to the COVID-19 pandemic could enroll in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days. The program has been extended until June 30, 2021. Eligibility criteria can be found on NovoCare.com or by calling 1.844.NOVO4ME (668.6463)
- My$99Insulin: My$99Insulin enables eligible patients to purchase up to three vials or two packs of FlexPen®/FlexTouch®/PenFill® pens of any combination of insulins for $99. Patients who enrolled in the My$99 Insulin program in 2020 should review the details of the program on NovoCare.com to determine if they are eligible to re-register in 2021
Novo Nordisk offers a number of other affordability programs, including:
- Our long-standing Patient Assistance Program (PAP), which has provided free medicines to eligible patients since 2003, has been enhanced to reflect today’s public health crisis. Historically, more than 50,000 patients have received free insulin each year through this program. Effective April 1, 2020, Medicare patients who qualify for PAP are no longer required to pay $1,000 for medicines before being eligible for the Novo Nordisk PAP
- Unbranded biologic insulins: Unbranded biologics of NovoLog® and NovoLog® Mix, from Novo Nordisk Pharma, Inc. (NNPI), a Novo Nordisk A/S US company, can be ordered at one’s local pharmacy and cost 50 percent off the current list prices of the branded medicines
- Immediate Supply: We also know that there may be instances when people are struggling and need insulin immediately because they might be at risk of rationing. People in this situation can call us at 1.844.NOVO4ME (1.844.668.6463) or visit NovoCare.com to see if we can provide a free, one-time, immediate supply of up to three vials or two packs of pens of Novo Nordisk insulin for individuals with a prescription
- Novo Nordisk human insulin is available at national pharmacies like Walmart and CVS for about $25/vial. About 500,000 Americans are using Novo Nordisk human insulin through these retailers
- Copay Savings Cards can help defray the costs for commercially insured patients who are experiencing high out-of-pocket costs
What is NovoCare?
NovoCare.com is Novo Nordisk’s go-to resource for all US patient affordability and access support programs. Available 24 hours a day, NovoCare.com provides all necessary information, including eligibility details, affordability options, assistance programs for those in need of insulin. Help is also available at 1.844.NOVO4ME (668.6463).
Call to Action: To learn more about these offerings and view full eligibility requirements, please visit NovoCare.com.